The first two blood cancer patients in a US-based trial, who had suffered relapses despite having treatment, have now been in remission for up to 120...
Vous n'êtes pas connecté
- English
- Français
- عربي
- Español
- Deutsch
- Português
- русский язык
- Català
- Italiano
- Nederlands, Vlaams
- Norsk
- فارسی
- বাংলা
- اردو
- Azərbaycan dili
- Bahasa Indonesia
- Հայերեն
- Ελληνικά
- Bosanski jezik
- українська мова
- Íslenska
- Türkmen, Түркмен
- Türkçe
- Shqip
- Eesti keel
- magyar
- Қазақ тілі
- Kalaallisut ; kalaallit oqaasii
- Lietuvių kalba
- Latviešu valoda
- македонски јазик
- Монгол
- Bahasa Melayu ; بهاس ملايو
- ဗမာစာ
- Slovenščina
- тоҷикӣ ; toğikī ; تاجیکی
- ไทย
- O'zbek ; Ўзбек ; أۇزبېك
- Tiếng Việt
- ភាសាខ្មែរ
- རྫོང་ཁ
- Soomaaliga ; af Soomaali
Maroc - THEWEST.COM.AU - Business - 10/Jul 06:42
Imugene delivers first Aussie bile tract cancer trial dose
Imugene has dosed its first of 10 Australian patients with its potent “VAXINIA” therapy as part of its phase-one bile tract cancer trial being conducted at St Vincent’s Hospital in Melbourne.
Articles similaires
ASX Health Stocks: Imugene reveals promise in lymphoma trial, stock soars 27pc
stockhead.com.au - 02/Sep 01:28
Imugene's stock has surged this morning, on promising Phase 1b results for its azer-cel allogeneic CAR T-cell therapy. ...
ASX Health Stocks: Imugene reveals promise in lymphoma trial, stock soars 27pc
stockhead.com.au - 02/Sep 01:28
Imugene's stock has surged this morning, on promising Phase 1b results for its azer-cel allogeneic CAR T-cell therapy. ...
Ifinatamab Deruxtecan Continues to Demonstrate Promising Objective Response Rates in Patients with Extensive-Stage Small Cell Lung Cancer in IDeate-Lung01 Phase 2 Trial
drugs.com - 07/Sep 06:09
BASKING RIDGE, N.J. & RAHWAY, N.J., September 7, 2024 – Results from an interim analysis of the dose-optimization part of the ongoing IDeate-Lung01...
Ifinatamab Deruxtecan Continues to Demonstrate Promising Objective Response Rates in Patients with Extensive-Stage Small Cell Lung Cancer in IDeate-Lung01 Phase 2 Trial
drugs.com - 07/Sep 06:09
BASKING RIDGE, N.J. & RAHWAY, N.J., September 7, 2024 – Results from an interim analysis of the dose-optimization part of the ongoing IDeate-Lung01...
First Patient Enrolled in Phase 1b/2 Triplet Therapy Trial of REZLIDHIA in mIDH1 AML
drugs.com - 06/Sep 07:09
SOUTH SAN FRANCISCO, Calif., Sept. 5, 2024. Rigel Pharmaceuticals, a commercial stage biotechnology company focused on hematologic disorders and...
Neurotech’s cannabinoid drug reverses immune dysregulation in PANDAS/PANS kids
stockhead.com.au - 09/Sep 04:15
Neurotech International has announced positive results of a genomic analysis conducted as part of its Phase 1/2 open-label clinical trial ...
Neurotech’s cannabinoid drug reverses immune dysregulation in PANDAS/PANS kids
stockhead.com.au - 09/Sep 04:15
Neurotech International has announced positive results of a genomic analysis conducted as part of its Phase 1/2 open-label clinical trial ...
CellProthera shares US regulatory progress of ProtheraCytes cell therapy programme
pharmabiz.com - 31/Aug 00:00
CellProthera, a regenerative cell therapy developer specialising in ischemic diseases, announced alignment with regulators on a planned pivotal phase...
Inquest hears details of innocent man shot dead in Bray on the orders of vengeful criminal
thejournal.ie - 29/Aug 15:40
Clinton McCormack (44) died at St Vincent’s University Hospital in Dublin on 19 December 2023.
Les derniers communiqués
-
Aucun élément